共 244 条
[1]
Ferlay J(2010)Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 765-81
[2]
Parkin DM(2004)Cancer of the ovary N Engl J Med 351 2519-29
[3]
Steliarova-Foucher E(2003)A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 1320-9
[4]
Cannistra SA(2010)Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer J Clin Oncol 28 4162-9
[5]
du Bois A(2006)Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO J Natl Cancer Inst 98 1036-45
[6]
Luck HJ(2003)Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 3194-200
[7]
Meier W(2006)EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours Eur J Cancer 42 2433-53
[8]
Adams HP(2005)Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1 J Clin Pharmacol 45 674-82
[9]
Mobus V(2006)Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel Clin Cancer Res 12 5786-93
[10]
Costa S(2005)Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel Clin Cancer Res 11 8097-104